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Abstract
Heparan sulfate is a polysaccharide that plays essential physiological functions in the animal 
kingdom. Heparin, a highly sulfated form of heparan sulfate, is a widely prescribed anticoagulant 
drug worldwide. The heparan sulfate and heparin isolated from natural sources are highly 
heterogeneous mixtures differing in polysaccharide chain lengths and sulfation patterns. The 
access to structurally defined heparan sulfate and heparin is critically important to probe the 
contribution of specific sulfated saccharide structures to biological functions as well as for the 
development of the next generation of heparin-based anticoagulant drugs. The synthesis of 
heparan sulfate and heparin, using a purely chemical approach, has proven extremely difficult, 
especially for targets larger than octasaccharides having a high degree of site-specific sulfation. A 
new chemoenzymatic method has emerged as an effective alternative approach. This method 
utilizes recombinant heparan sulfate biosynthetic enzymes combined with unnatural uridine 
diphosphate-monosaccharide donors. Recent examples demonstrate the successful synthesis of 
ultra-low molecular weight heparin, low-molecular weight heparin and bioengineered heparin with 
unprecedented efficiency. The new method opens the opportunity to develop improved heparin-
based therapeutics.
Introduction
Heparan sulfate (HS) is a polysaccharide-based natural product, widely expressed on the 
mammalian cell surfaces and in the extracellular matrix. Large body of evidence 
demonstrate that HS plays essential roles in a number of biological processes, including 
embryonic development, inflammatory responses, bacterial/viral infection and blood 
coagulation.1 The wide range of biological functions has attracted considerable interest in 
the development of new medicines using HS as a structural scaffold. Heparin, a specialized, 
highly sulfated form of HS, is a widely used anticoagulant to prevent and treat arterial and 
venous thrombosis.2,3 HS consists of a disaccharide repeating unit of either iduronic acid 
(IdoA) or glucuronic acid (GlcA) and glucosamine (GlcN) residues, each capable of 
carrying sulfate groups (Fig. 1). The presence of sulfate groups and the location of IdoA and 
GlcA residues dictate the functional selectivity of HS. The challenge in developing HS-
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based drugs centers on the synthesis of HS oligosaccharides and polysaccharides having 
desired size and sulfation patterns. HS oligosaccharides have been synthesized by a purely 
chemical approach; however, this synthesis is difficult, due to the required use of complex 
protecting/deprotecting procedures. The syntheses of diversified HS structures are further 
complicated because they require the preparation of a large number of precursor compounds. 
Therefore, HS oligosaccharide synthesis can be completed by skilled synthetic chemists in a 
small number of highly specialized labs.4-13 In recent years, a chemoenzymatic synthesis 
has emerged using glycosyltransferases, epimerase and sulfotransferases.14,15 Compared to 
chemical synthesis, the chemoenzymatic approach offers shorter synthetic routes, excellent 
recovery yields, and utilizes a few common precursors for the preparation of diverse HS 
oligosaccharide structures. This article reviews the recent development in the 
chemoenzymatic synthesis method and its progress towards the synthesis of HS 
oligosaccharide targets having diverse sulfation patterns.
Heparin
Discovered in 1916, heparin has been the drug of choice to treat thrombotic disorders for 
nearly 90 years.16 The discovery of heparin contributed significantly to the development of 
many advanced medical and surgical procedures.17 Three forms of heparin are approved by 
the US Food and Drug Administration (FDA): Unfractionated heparin ((UFH) average 
molecular weight (MWavg) 16,000 Da), low-molecular weight heparin (MWavg 3,500-6,000 
Da) and fondaparinux (MW 1,508 Da). UFH is a safe intravenous drug for the treatment of 
renal-impaired patients and its effects can be reversed using the cationic-polypeptide drug 
protamine;18 however, it shows a 1-6% incidence of heparin-induced thrombocytopenia 
(HIT), a life-threatening complication.19 LMWHs are subcutaneously administered and have 
a longer half-life than UFH, permitting their outpatient use and self-administration. 16 
However, LMWH can only be used in renal-impaired patients at the reduced doses20 and is 
incompletely neutralized with protamine, thereby increasing the risks of bleeding. 
Fondaparinux, a synthetic pentasaccharide, is subcutaneously bioavailable and has reduced 
risks of HIT and osteoporosis.21 However, it is primarily excreted through the kidney and, 
thus, is not suitable for renal-impaired patients, and it lacks an antidote.20
Both UFH and LMWH are considered to be animal-sourced products. 22 UFH is isolated 
from porcine intestine or bovine lung or intestine, while LMWHs are a depolymerized 
product of heparin from porcine intestine. A worldwide contamination of heparin in 2007 
affected the purity and safety of both UFH and LMWHs associated with over 200 deaths in 
the US. 23,24 This incident revealed the fragility of the heparin supply chain. Although 
fondaparinux is fully synthetic,11 and its supply does not depend on the animal sources, the 
drug does not display all clinical benefits as those of UFH and LMWH. A cost-effective 
method to prepare a synthetic heparin and LMWH that can be manufactured under FDA’s 
guidelines will eliminate the needs of animal sourced materials.24 Furthermore, the synthetic 
heparins could be engineered to introduce additional beneficial pharmacological properties 
that do not exist in UFH and LMWHs from natural sources.16
Heparin and HS have similar disaccharide repeating units; however, heparin has higher 
sulfation levels than HS, containing 2.6 sulfo groups per disaccharide compared to 0.6 sulfo 
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groups in HS. In addition, nearly 90% of the disaccharide units in heparin contain IdoA, 
while only 20% of the disaccharide units in HS contain IdoA. HS can be isolated from many 
cell types, whereas heparin is an exclusive product of mast cells.
Enzymes involved in the chemoenzymatic synthesis
The chemoenzymatic synthesis of HS requires several classes of biosynthetic enzymes, 
some comprised of multiple isoforms.25 Glycosyltransferases are used to build the HS 
backbone structure consisting of a disaccharide repeating unit of GlcA and N-
acetylglucosamine (GlcNAc).26 An epimerase (C5-epi) is responsible for converting a GlcA 
residue to an IdoA residue.27 Sulfo groups are transferred from 3′-phosphoadenosine-5′-
phosphosulfate (PAPS) to oligosaccharide by specialized HS sulfotransferases. For example, 
2-O-sulfotransferase (2-OST) specifically transfers a sulfo group to the 2-position of an 
IdoA residue and, to lesser extent, to the 2-position of a GlcA residue.28,29 The 6-O-
sulfotransferase (6-OST) and the 3-O-sulfotransferase (3-OST) transfer sulfo groups to the 
6-position and 3-position of glucosamine residues. 29,30 N-deacetylase/N-sulfotransferase 
(NDST) converts a GlcNAc residue to a N-sulfoglucosamine (GlcNS) residue.31 NDST is 
unique displaying two activities, N-deacetylase activity removing N-acetyl group from a 
GlcNAc residue, and N-sulfotrasnferase activity transferring a sulfo group to a GlcN 
residue, forming a GlcNS residue.32,33
The enzymes used for the chemoenzymatic synthesis of heparin are predominantly 
mammalian proteins, presenting challenges for making these recombinant proteins 
accessible in large quantities. Currently, most of these HS biosynthetic enzymes, with the 
exception of NDST, EXT-1 and EXT-2, have been expressed in E. coli with sufficient 
efficiency for high milligram-scale synthesis. 34 Only the N-sulfotransferase (NST) domain 
of the NDST can be effectively expressed in E. coli and, thus, this protein lacks N-
deacetylase activity. Two bacterial glycosyltransferases known as KfiA (an N-acetyl 
glucosaminyl transferase from E. coli K5 strain) and pmHS2 (heparosan synthase 2 from 
Pasteurella multicida) are used as substitute EXT1 and EXT2, to build HS backbone. Both 
KfiA and pmHS2 enzymes can be readily expressed in E. coli.35,36
Design of sugar nucleotides for the chemoenzymatic synthesis of HS
Chemoenzymatic synthesis of HS requires a cascade of enzymatic modifications. The N-
sulfation of glucosamine is essential for the down-stream enzymatic modifications to 
occur.25 The synthesis of the HS backbone containing GlcNS residues represented a major 
roadblock due to the lack of efficient recombinant NDST. An unnatural sugar 
nucleotide,37,38 UDP-GlcNTFA (uridine diphosphate N-trifluoroacetylated glucosamine), 
was introduced to overcome this problem. The UDP-GlcNTFA was first reportedly used in 
the synthesis of carbohydrates of O-linked glycoprotein by “core-2” GlcNAc transferase 
with modest yield (56%).39 For HS backbone synthesis, UDP-GlcNTFA appears to be an 
excellent substrate for KfiA with nearly quantitative conversion in the preparation of heparin 
oligosaccharide backbone.40 The GlcNTFA residue is then converted to a GlcNS residue by 
removing the trifluoroacetyl group under mild alkaline conditions followed by N-
sulfotransferase modification (Fig. 3). The use of UDP-GlcNTFA provides a means to 
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introduce a GlcNS at precisely the desired position within an oligosaccharide. This strategy 
is now used to synthesize structurally homogeneous ultra-low molecular weight heparins, 
low-molecular weight heparins14,15 and heterogeneous heparin-like polysaccharides.41,42
A novel strategy to utilize a series of unnatural sugar nucleotides to synthesize heparin-like 
oligosaccharide was recently proposed by Chen and coworkers. 43 Here, the 6-hydroxyl 
group of GlcN was substituted by an azido group to synthesize sugar nucleotides, including 
UDP-[6-azido]GlcNAc or UDP-[6-azio]GlcNTFA. Chen and coworkers demonstrated the 
synthesis of oligosaccharides, which carry the azido groups at the 6-position of the GlcN 
residue, in excellent yields using pmHS2 enzyme. The azido group was then converted to an 
amino group followed by N-sulfation to generate 6-N-sulfo GlcN residues. Ultimately, HS-
analog oligosaccharides, containing N-sulfate groups at both the 2- and the 6-positions of 
GlcN were synthesized, mimicking the 2-N-sulfo, 6-O-sulfo GlcN residues in natural HS 
and heparins. Because this synthesis only involves the use of glycosyltransferase and 
chemoselective N-sulfation to produce sulfated saccharides, the approach eliminates the 
potential complexity in introducing a sulfate group at a desired site by relying on the 
substrate specificity of the O-sulfotransferases. Because of this unnatural 6-N-sulfation these 
products might be resistant to heparanase and lysosomal degradation, increasing the 
biological half-life of oligosaccharides.
Design of the sequence of enzymatic modifications
The chemoenzymatic synthesis of heparin requires a series of enzymatic modification steps. 
The design of an appropriate modification sequence is closely related to the substrate 
specificities of the biosynthetic enzymes. In vivo, a HS biosynthetic pathway is responsible 
for installing the multiple layers of sulfation on the polysaccharide backbone by following a 
specific order. The cells probably utilize the modification sequence to achieve the control of 
HS polysaccharide structure. HS biosynthetic enzymes have evolved to only react with 
select substrates having unique sulfation patterns, while other saccharide substrates lacking 
these sulfation patterns remain unmodified. Such a feature assures the biosynthesis of HS 
follows a preprogrammed modification sequence. 44 For example, 2-O-sulfation step 
catalyzed by 2-OST occurs only after N-sulfation step, but prior to the 6-O-sulfation step. 
The ternary crystal structure of 2-OST reveals that three amino acid residues, Arg-80, 
Lys-350 and Arg-190, from 2-OST directly interact with the N-sulfo group of GlcNS residue 
flanked on both end of the IdoA residue. Mutation any of three residues that are interacted 
with the N-sulfo group resulted in the lost of sulfotransferase activity. Likewise, substituting 
the N-sulfo group with an N-acetyl group or hydrogen on the GlcN residue of the substrate 
abolishes its reactivity to 2-OST modification. 44 In contrast, two amino acid residues, 
Tyr-173 and Pro-82 near that active site of 2-OST are probably used by the enzyme to 
exclude the 6-O-sulfo group, suggesting that 6-O-sulfation occurs after 2-O-sulfation in the 
process of biosynthesizing highly sulfated domains consisting of -IdoA2S-GlcNS6S-, 
commonly found in heparin. The structural and biochemical evidence clearly demonstrates 
the essential roles of N-sulfation and 6-O-sulfation in regulating the 2-O-sulfation in the HS 
biosynthetic pathway.
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Synthesis of oligosaccharides with repeating –IdoA2S-GlcNS- units
The synthesis of a domain with repeating –IdoA2S-GlcNS- disaccharide units is critically 
important for preparing heparin and the high sulfation domains of HS. In heparin, more than 
80% of the disaccharides are composed of -IdoA2S-GlcNS6S-.3 Attempts to synthesize a 
domain with more than one -IdoA2S-GlcNS- motif results in a complex mixture. 45 
Complex product mixtures are acceptable when preparing bioengineered heparin46 as a 
generic replacement for animal-sourced UFHs, since these products are polydisperse and 
microheterogenous. 3 The challenge comes in synthesizing structurally defined LMWHs or 
ULMWHs containing repeating –IdoA2S-GlcNS6S-motifs. The difficulty in installing 
repeating –IdoA2S-GlcNS6S units stems from a unique property of C5-epi. Unlike other HS 
biosynthetic enzymes, C5-epi is a two-way catalyst: it transforms a GlcA to an IdoA residue, 
and also converts an IdoA to a GlcA residue (Fig. 4A). 47 Therefore, the final product is a 
mixture of GlcA and IdoA after C5-epi modification. A recent study revealed that C5-epi is a 
one-way catalyst towards substrates having a unique distribution of GlcNAc and GlcNS 
residues. 48 The results indicate that C5-epi can display both two-way and one-way catalytic 
modes by recognizing a sequence motif designated as the C5-epi recognition 
pentasaccharide domain (Fig. 4B). 48 This pentasaccharide domain consists of an 
epimerization site (EPS) and a mode of reaction recognition site (MRRS). The MRRS is 
located three residues away from the non-reducing end side of the EPS (Fig. 4B). The N-
substitution status of the MRRS residue, controlled in biosynthesis by NDST, 49 dictates the 
mode of action of C5-epi. A GlcNAc residue directs C5-epi to display an irreversible 
reaction mode, while a GlcNS or GlcN residue (or the MRRS site being unoccupied) drives 
C5-epi to display a reversible reaction mode. The presence of GlcNS at the -1 residue is 
essential for rendering the susceptibility to C5-epi modification.
An improved knowledge on the substrate specificity of C5-epi offers an alternative strategy 
for synthesizing IdoA2S-GlcNS repeating units to avoid forming by-products (Fig. 5). Seven 
steps (Fig. 5, Steps a, b, a, b, c, a, and d, transformation of 1 to 8) are required to synthesize 
the first IdoA2S residue from a monosaccharide starting material. Each repetition of these 
steps adds an additional IdoA2S residues, transforming 8 to 12, 13 and 14, containing two, 
three and four IdoA2S-GlcNS repeats, respectively. The construction of a C5-epi recognition 
pentasaccharide module with the structure of GlcNTFA-GlcA-GlcNS-GlcA-GlcNS- is the 
centerpiece of this strategy (Fig. 4, compound 7). This pentasaccharide module allows C5-
epi to exhibit the irreversible reaction mode, leading to a single product. The resultant IdoA 
residue in the pentasaccharide domain is immediately 2-O-sulfated to form an IdoA2S 
residue (Fig. 5, compound 8). Subsequent construction of the C5-epi recognition 
pentasaccharide module involves three steps (Fig. 5, Step c, b and a) to introduce additional 
-IdoA2S-GlcNS- motifs. For example, compound 8 will be elongated to an octasaccharide 
with a structure of GlcNTFA-GlcA-GlcNS-GlcA-GlcNS-IdoA2S-GlcNS-GlcApnp 
(compound 11), containing the C5-epi recognition pentasaccharide domain (highlighted in 
bold). The modifications by C5-epi and 2-OST (Step d and e) will result in an octasaccharide 
of GlcNTFA-GlcA-GlcNS-IdoA2S-GlcNS-IdoA2S-GlcNS-GlcApnp (compound 12). The 
2-O-sulfation to form an IdoA2S residue is essential because it prevents further action of C5-
epi on this residue and accelerates the C5-epimerization reaction.47 These steps can be 
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further repeated to form deca- (13) and dodecasaccharide (14) to introduce three and four 
repeats of IdoA2S-GlcNS disaccharides as described in a recent publication. 15
Using the chemoenzymatic method to design heparin drugs
Two specific examples for the utilization of chemoenzymatic approach to prepare heparin 
oligosaccharides with anticoagulant activity have been recently demonstrated. In the first 
example, this method was used to synthesize a homogenous heptasaccharide (Fig. 6). The 
synthesis, initiated from a disaccharide (GlcA-AnMan, AnMan represents 2,5-
anhydromannitol), was completed in nine enzymatic steps with 43% recovery yield. 14 The 
synthesis includes the elongation of the starting disaccharide to a heptasaccharide using 
KfiA and pmHS2. The heptasaccharide backbone is then converted to final product by a 
series of reactions, including conversion of the GlcNTFA residue to GlcNS (Fig. 6, step c), 
epimerization and 2-O-sulfation (Fig. 6, step e and f), 6-O-sulfation (Fig. 6, step g) and 3-O-
sulfation (Fig. 6, step h). The product has very similar anticoagulant potency to that of 
fondaparinux as measured by in vitro and ex vivo experiments. Synthesis of fondaparinux 
using a purely chemical approach requires a much longer route to complete. 11,50
The second example is to design the structures of LMWHs with desired pharmacological 
properties (Fig. 7). Desirable properties of LMWHs include: a homogeneous structure 
prepared from non-animal ingredients, safe for kidney-impaired patients, and has reversible 
anticoagulant activity. Toward these goals, five different oligosaccharides were 
synthesized. 15 Among these were 6-mer ULMW heparin target compound, very similar to 
fondaparinux, as well as a 10-mer and 12-mer that were in the size range of LMWHs. 
Because of the size and structural complexity of LMWHs, a more efficient chemoenzymatic 
method was required. A commercially available aglycone, 1-O-(para-nitrophenyl) 
glucuronide (GlcA-pNP), was used as a starting material. The presence of pNP motif 
provides a UV chromophore for monitoring the product during the synthesis and 
purification. Nonsulfated oligosaccharides carrying this pNP motif bind to conventional 
C18-columns, allowing easy purification of intermediates from proteins and unreacted 
cofactors. Moreover, this pNP group can be removed at the end of the synthesis or reduced 
to afford an amino group51 for attaching the resulting oligosaccharide to a support. A unique 
enzymatic modification sequence was employed on the GlcA-pNP to synthesize the 
oligosaccharides consisting of the repeating disaccharide unit of –IdoA2S-GlcNS-, having 
high purity (Fig. 5). The final products were purified by anion exchange chromatography to 
obtain a purity of > 98%. In a mouse model, oligosaccharides larger than 10-mer were 
metabolized in the liver, suggesting that these synthetic LMWHs will be safe for use in 
renal-impaired patients. Most interestingly, the anticoagulant activity of the synthetic 
LMWH 12-mer was reversed by protamine, an FDA approved drug to neutralize 
unfractionated heparin. The protamine reversibility of this 12-mer could potential reduce the 
risk of bleeding in its clinical use.
Conclusions
Over the past five years, there has been steady improvement in the chemoenzymatic 
synthesis of HS and heparin oligosaccharides, focused on making synthesis more flexible for 
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the preparation of different targets with increased purity and increased synthetic scale. To 
date, more than 32 heparin oligosaccharides have been synthesized (Table 1). The scale of 
synthesis has increased from 10 μg as reported in 200352 to 1g, a 100,000-fold increase.15 
This improvement in synthesis is attributable to improved enzyme expression, higher 
efficiency synthesis for enzyme cofactors and an improved understanding of the substrate 
specificities of HS biosynthetic enzymes. The availability of these newly synthesized 
compounds has improved heparin and HS research. For example, synthetic heparin 
oligosaccharides prepared by chemoenzymatic synthesis were used to solve the co-crystal 
structure of 3-OST-1/PAP/heptasaccharide and 2-OST/heptasaccharides/3′-
phosphoadenosine-5′-phosphate.44,53 These crystal structures helped us understand how 
sulfotransferases distinguish the specific saccharide sequences to exhibit substrate 
specificity. The results from these studies will, in turn, further improve oligosaccharide the 
synthesis using these enzymes.
The next challenge in anticoagulant drug development is to synthesize homogeneous 
LMWHs that meet all of the current clinical needs. The synthesis of the LMWH 12-mer 
requires 22 synthetic steps with the overall yield about 10%. This chemoenzymatic synthesis 
is significantly shorter than the chemical synthesis of fondaparinux that requires 50 steps. 54 
Fondaparinux is now synthesized in kg-scale, and has been a profitable drug for ten years. 55 
Further development of the chemoenzymatic approach should result in cost-effective 
products, accelerating the modernization of LMWH drugs as well as defined HS 
oligosaccharides for biomedical researches.
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Structures of the disaccharide repeating unit of HS and the structure of fondaparinux.
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Fig 2. Enzymes involved in the biosynthesis of HS
Panel A shows the elongation reactions to prepare nonsulfated and unepimerized saccharide 
backbone. Both EXT1 and EXT2 proteins are involved in the elongation reactions. Panel B 
shows the reactions involved in polysaccharide modifications. The sites of reactions are 
highlighted in grey boxes. Abbreviations: EXT1; exostosin glycosyltransferase 1; EXT1; 
exostosin glycosyltransferase 2; NDST, N-deacetylase/N-sulfotransferase; C5-epi, C5-
epimerase; 2-OST, 2-O-sulfotransferase; 6-OST, 6-O-sulfotransferase; 3-OST, 3-O-
sulfotransferase; PAPS, 3′-phosphoadenosine 5′-phosphosulfate.
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Fig 3. Building HS backbone containing GlcNS residues using a non-natural sugar nucleotide
KfiA transfers a GlcNAc residue to the primer substrate, where the sugar nucleotide donor is 
UDP-GlcNAc, a natural substrate for KfiA. KfiA also transfers a GlcNTFA residue to the 
primer substrate, where the sugar nucleotide donor is UDP-GlcNTFA, an unnatural sugar 
nucleotide. The trifluoroacetyl group can be removed under mild base conditions to form an 
N-unsubstituted glucosamine (GlcN) residue. The GlcN residue is then converted to GlcNS 
by N-sulfotransferase (NST). The removal of trifluoroacetyl group can be achieved by 
triethylamine and methanol under room temperature, or by 0.1 M LiOH at 4°C. The 
synthesis of UDP-GlcNTFA is completed in two-step synthesis using N-acetylhexosamine 
1-kinase and glucosamine-1-phosphate acetyltransferase/N-acetylglucosamine-1-phosphate 
uridyltransferase (GlmU).
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Fig 4. The reaction catalyzed by C5-epi and its substrate specificity
A shows the reaction catalyzed by C5-epi. A trisaccharide segment is shown. C5-epi removes 
the proton from C5 of the GlcA residue to form a putative carbanion intermediate. 
Conversely, C5-epi can catalyze the reverse reaction, converting an IdoA residue to a GlcA 
residue. B shows the substrate specificity of C5-epi. The designated epimerization site (EPS) 
is at the residue 0. The residue -1 must be a GlcNS residue to serve as an EPS. If residue -1 
is a GlcNAc residue, the site is not reactive to C5-epi (see reaction e). The N-substitution 
status at the mode of reaction recognition site (MRRS) determines the mode of reaction of 
C5-epi. If the MRRS site (residue -3) is a GlcNS or GlcN residue or unoccupied, C5-epi 
displays a reversible reaction mode (see reaction a, c and b). If a GlcNAc residue is at the 
MRRS site, C5-epi displays an irreversible reaction mode (see reaction d). The grey shaded 
box indicates the pentasaccharide domain recognized by C5-epi.
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Fig 5. Route to synthesize oligosaccharides with IdoA2S-GlcNS repeats
The key in this strategy is to construct a C5-epi recognition pentasaccharide module to 
utilize the irreversible reaction. The C5-epi recognition pentasaccharide module is 
highlighted in a grey box. The synthesis initiates from GlcA-pnp (1, p-nitrophenyl 
glucuronide). The monosaccharide is converted to a pentasaccharide 5 in four enzymatic 
steps. Hexasaccharide 7 consists of the C5-epi recognition pentasaccharide module. The 
synthesis of 8 from 7 is achieved by two enzymatic steps (step d) using both C5-epi and 2-
OST. Hexasaccharide 8 contains a single IdoA2S-GlcNS disaccharide unit. The construction 
of another C5-epi recognition pentasaccharide module involves four enzymatic steps, b, c, a 
and d (transformation of 8 to 12). Repeating those steps can reach to 13 and 14.
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Route for the chemoenzymatic synthesis of ultra-low molecular weight heparin.
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Fig 7. Structure of synthetic low-molecular weight heparins
The synthetic LMWH 12-mer has two 3-O-sulfo groups.
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Table 1
Summary of synthesized HS oligosaccharides using the chemoenzymatic approach
Compounds Structure Comments Reference
16-19 GlcA-GlcNR1-GlcA-GlcNR2-GlcA-GlcNAc-GlcA-AnMan
(16, R1=R2=Ac; 17, R1=SO3H, R2=Ac; 18, R1=Ac,
R2=SO3H; 19, R1=R2=SO3H)
Demonstration of the
control of size and N-
sulfation
40
20 and 21 GlcA-GlcNS6S-(GlcA-GlcNS6S)n-GlcA-AnMan (20, n =
3; 21, n = 4)
Demonstration of the
control of complete 6-O-
sulfation
40
22 and 23 GlcNR’6S-GlcA-GlcNS3S6S-IdoA2S-GlcNS6S-GlcA-


























GlcNR46S-GlcA-pNP (31, R1=R2=R3=R4=SO3H; 32,
R1=Ac; R2=R3=R4=SO3H; 33, R1=R2=Ac, R3=R4=SO3H;
34, R1=R4=Ac, R2=R3=SO3H; 35, R1=R2=R3=SO3H,
R4=Ac; 36, R1=R2=Ac, R2=R2=SO3H)
Demonstration of the
synthesis of a small




37-40 GlcNR-GlcA-GlcNS-(IdoA2S-GlcNS)m-GlcA-pNP (37, R
=−SO3H, m =1;38, R =−SO3H; m=2; 39, R = −SO3H; m







pNP (41, R =−SO3H, m =1;42, R =−SO3H; m=2; 43, R = −
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